This is a non-core endpoint: only basic statistics are computed.
Carcinoma in situ, other/unspecified (controls excluding all cancers)
CD2_INSITU_NOS_EXALLC
No definition available.
Endpoint definition
↥individuals
Apply sex-specific rule None
Check conditions None
Check pre-conditions, main-only, mode, registry filters
2 out of 7 registries used, show all original rules.
-
Check minimum number of events None
-
Include endpoints None
-
Remove individuals based on genotype QC
17
Control definitions
Extra metadata
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to Carcinoma in situ, other/unspecified (controls excluding all cancers) based on the number of shared cases.
Broader endpoints:
- Carcinoma in situ, other/unspecified
- Carcinoma in situ of other and unspecified sites
- Carcinoma in situ of other and unspecified sites (controls excluding all cancers)
- In situ neoplasms
- In situ neoplasms (controls excluding all cancers)
Narrower endpoints:
Summary Statistics
↥Key figures
All | Female | Male | |
---|---|---|---|
Number of individuals | 17 | 6 | 11 |
Unadjusted prevalence (%) | 0.00 | 0.00 | 0.01 |
Mean age at first event (years) | 71.85 | 68.25 | 73.81 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_INSITU_NOS_EXALLC – Carcinoma in situ, other/unspecified (controls excluding all cancers)
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Carcinoma in situ, other/unspecified (controls excluding all cancers)
↥Endpoint not on priority list, no data to show.